TherapeuticsMD(TXMD)
$1.85+0.11 (+6.32%)
TXMD
TherapeuticsMD financials statements
$1.85
At close:+0.11 (+6.32%)
Want to see TXMD full AI Analyst Report?
TherapeuticsMD (TXMD) Ratios
2,250 Followers
TherapeuticsMD Ratios
TXMD's free cash flow for Q2 2026 was $770.00K. For the 2026 fiscal year, TXMD's free cash flow was increased by $0.00 and operating cash flow was $770.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.02 | 1.92 | 1.72 | 1.18 | 0.47 |
| Quick Ratio | 3.02 | 1.92 | 1.72 | 1.18 | 0.44 |
| Cash Ratio | 1.56 | 0.98 | 0.63 | 0.81 | 0.26 |
| Solvency Ratio | 0.06 | -0.15 | -0.70 | 2.05 | -0.65 |
| Operating Cash Flow Ratio | 0.51 | 0.14 | -7.02 | -0.09 | -0.58 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.45 | 0.00 | 0.00 | -0.79 |
| Net Current Asset Value | $ 3.67M | $ -1.53M | $ -2.23M | $ 36.00K | $ -143.63M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.16 | 0.18 | 0.18 | 0.10 | 1.17 |
| Debt-to-Equity Ratio | 0.23 | 0.26 | 0.27 | 0.25 | -2.11 |
| Debt-to-Capital Ratio | 0.18 | 0.21 | 0.21 | 0.20 | 1.90 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.40 | 1.42 | 1.48 | 2.57 | -1.81 |
| Debt Service Coverage Ratio | -377.63 | -1.80 | 0.00 | 0.00 | -0.32 |
| Interest Coverage Ratio | -526.75 | -501.05 | 0.00 | 0.00 | -2.42 |
| Debt to Market Cap | 0.00 | 0.16 | 0.00 | 0.00 | 1.31 |
| Interest Debt Per Share | 0.53 | 0.62 | 0.77 | 0.97 | 28.97 |
| Net Debt to EBITDA | 0.46 | -0.71 | -0.45 | -2.47 | -1.87 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 98.00% | 45.51% |
| EBIT Margin | -139.44% | -198.30% | -654.61% | 15.24% | -2781.85% |
| EBITDA Margin | -99.97% | -169.39% | -620.93% | 16.96% | -2753.25% |
| Operating Profit Margin | -139.44% | -270.30% | -654.61% | 1.70% | -3092.77% |
| Pretax Profit Margin | -21.61% | -133.05% | -594.62% | 1.54% | -3082.20% |
| Net Profit Margin | -18.83% | -123.85% | -789.40% | 160.08% | -6700.93% |
| Continuous Operations Profit Margin | -21.61% | -131.29% | -591.32% | 1.54% | -3082.20% |
| Net Income Per EBT | 87.14% | 93.09% | 132.76% | 10428.03% | 217.41% |
| EBT Per EBIT | 15.50% | 49.22% | 90.84% | 90.18% | 99.66% |
| Return on Assets (ROA) | -1.51% | -5.62% | -23.73% | 123.81% | -101.74% |
| Return on Equity (ROE) | -2.12% | -7.97% | -35.09% | 318.69% | 184.16% |
| Return on Capital Employed (ROCE) | -12.82% | -14.14% | -23.38% | 2.73% | 95.39% |
| Return on Invested Capital (ROIC) | -12.45% | -13.31% | -22.35% | 2.65% | -74.92% |
| Return on Tangible Assets | -1.68% | -6.32% | -27.62% | 134.10% | -106.21% |
| Earnings Yield | -3.02% | -21.99% | -43.75% | 221.92% | -120.33% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.86 | 0.49 | 0.42 | 0.00 | 0.07 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.65 | 0.42 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 |
| Fixed Asset Turnover | 0.57 | 0.29 | 0.19 | 9.14 | 0.28 |
| Asset Turnover | 0.08 | 0.05 | 0.03 | 0.77 | 0.02 |
| Working Capital Turnover Ratio | 0.42 | 0.36 | 0.19 | -1.12 | -0.08 |
| Cash Conversion Cycle | 425.75 | 738.29 | 866.24 | -564.87 | 6238.04 |
| Days of Sales Outstanding | 425.75 | 738.29 | 866.24 | 0.00 | 5131.85 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 1984.33 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 564.87 | 878.13 |
| Operating Cycle | 425.75 | 738.29 | 866.24 | 0.00 | 7116.18 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.21 | 0.06 | -4.61 | -0.45 | -18.57 |
| Free Cash Flow Per Share | 0.21 | 0.06 | 0.00 | -0.49 | -18.57 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -1.00 | -11.49 | -4347.38 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -1.00 | -11.49 | -4347.38 |
| Operating Cash Flow Coverage Ratio | 0.40 | 0.10 | -6.01 | -0.47 | -0.75 |
| Operating Cash Flow to Sales Ratio | 0.80 | 0.42 | -36.97 | -0.06 | -57.45 |
| Free Cash Flow Yield | 12.85% | 7.38% | 0.00% | -8.78% | -103.19% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -33.13 | -4.53 | -2.29 | 0.45 | -0.83 |
| Price-to-Sales (P/S) Ratio | 6.24 | 5.63 | 18.04 | 0.72 | 55.69 |
| Price-to-Book (P/B) Ratio | 0.70 | 0.36 | 0.80 | 1.44 | -1.53 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 7.78 | 13.55 | 0.00 | -11.38 | -0.97 |
| Price-to-Operating Cash Flow Ratio | 7.78 | 13.55 | -0.49 | -12.38 | -0.97 |
| Price-to-Earnings Growth (PEG) Ratio | 0.45 | 0.07 | 0.02 | -0.01 | 0.03 |
| Enterprise Value Multiple | -5.78 | -4.03 | -3.36 | 1.78 | -3.90 |
| Enterprise Value | 17.47M | 12.03M | 27.17M | 21.16M | 276.07M |
| EV to EBITDA | -5.78 | -4.03 | -3.36 | 1.78 | -3.90 |
| EV to Sales | 5.78 | 6.83 | 20.87 | 0.30 | 107.29 |
| EV to Free Cash Flow | 7.21 | 16.44 | 0.00 | -4.77 | -1.87 |
| EV to Operating Cash Flow | 7.21 | 16.44 | -0.56 | -5.19 | -1.87 |
| Tangible Book Value Per Share | 2.00 | 2.00 | 2.22 | 3.12 | -12.66 |
| Shareholders’ Equity Per Share | 2.32 | 2.37 | 2.80 | 3.89 | -11.76 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Revenue Per Share | 0.26 | 0.15 | 0.12 | 7.75 | 0.32 |
| Net Income Per Share | -0.05 | -0.19 | -0.98 | 12.41 | -21.66 |
| Tax Burden | 0.87 | 0.93 | 1.33 | 104.28 | 2.17 |
| Interest Burden | 0.15 | 0.67 | 0.91 | 0.10 | 1.11 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 2.27 | 3.46 | 0.00 | 0.83 | 28.27 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 |
| Income Quality | -3.71 | -0.32 | 6.25 | -3.80 | 1.86 |
Currency in USD
